Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Rena R. Wing,Wei Lang,Thomas A. Wadden,Monika M. Safford,William C. Knowler,Alain G. Bertoni,James O. Hill,Frederick L. Brancati,Anne L. Peters,Lynne E. Wagenknecht +9 more
Reads0
Chats0
TLDR
Modest weight losses of 5 to <10% were associated with significant improvements in CVD risk factors at 1 year, but larger weight losses had greater benefits.Abstract:
OBJECTIVE Overweight and obese individuals are encouraged to lose 5–10% of their body weight to improve cardiovascular disease (CVD) risk, but data supporting this recommendation are limited, particularly for individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS We conducted an observational analysis of participants in the Look AHEAD (Action For Health in Diabetes) study ( n = 5,145, 40.5% male, 37% from ethnic/racial minorities) and examined the association between the magnitude of weight loss and changes in CVD risk factors at 1 year and the odds of meeting predefined criteria for clinically significant improvements in risk factors in individuals with type 2 diabetes. RESULTS The magnitude of weight loss at 1 year was strongly ( P P = 0.79). Compared with weight-stable participants, those who lost 5 to 1c (odds ratio 3.52 [95% CI 2.81–4.40]), a 5-mmHg decrease in diastolic blood pressure (1.48 [1.20–1.82]), a 5-mmHg decrease in systolic blood pressure (1.56 [1.27–1.91]), a 5 mg/dL increase in HDL cholesterol (1.69 [1.37–2.07]), and a 40 mg/dL decrease in triglycerides (2.20 [1.71–2.83]). The odds of clinically significant improvements in most risk factors were even greater in those who lost 10–15% of their body weight. CONCLUSIONS Modest weight losses of 5 toread more
Citations
More filters
Journal ArticleDOI
The Kidney as a Treatment Target for Type 2 Diabetes
TL;DR: Results from clinical trials show that these compounds decrease plasma glucose and body weight in treatment-naive patients and in patients receiving metformin or insulin and insulin sensitizers, and SGLT2 inhibition presents an additional option to promote glycemic control in patients with type 2 diabetes.
Journal ArticleDOI
Weight control behaviors according to body weight status and accuracy of weight perceptions among Korean women: a nationwide population-based survey
Boyoung Park,Ha Na Cho,Eunji Choi,Da Hea Seo,Nam Soon Kim,Eunja Park,Sue Kim,Yeong Ran Park,Kui Son Choi,Yumie Rhee +9 more
TL;DR: In this paper, the authors identify associations among self-perceived weight status, accuracy of weight perceptions, and weight control behaviors, including both healthy and unhealthy behaviors, in a large, nationally representative sample from an East Asian country.
Journal ArticleDOI
A nonrestrictive, weight loss diet focused on fiber and lean protein increase.
Lijuan Zhang,Lijuan Zhang,Sherry L. Pagoto,Barbara C. Olendzki,Gioia Persuitte,Linda C. Churchill,Jessica L. Oleski,Yunsheng Ma +7 more
TL;DR: A diet that promotes increased fiber and lean protein intake demonstrates feasibility and high acceptability ratings, which resulted in calorie and weight reductions and an improvement of the dietary quality.
Journal ArticleDOI
New Insights in the Prevention and Early Management of Type 2 Diabetes
Journal ArticleDOI
Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
Simon Jensen,Simon Jensen,Julie R. Lundgren,Julie R. Lundgren,Charlotte Janus,Charlotte Janus,Christian R. Juhl,Christian R. Juhl,Lisa M. Olsen,Lisa M. Olsen,Mads Rosenkilde,Mads Rosenkilde,Jens J. Holst,Jens J. Holst,Bente Stallknecht,Sten Madsbad,Signe S. Torekov,Signe S. Torekov +17 more
TL;DR: This study investigates the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.
References
More filters
Journal ArticleDOI
Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
TL;DR: A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
Journal Article
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults : the evidence report
Journal ArticleDOI
Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
TL;DR: A prospective, controlled Swedish Obese Subjects Study involved obese subjects who underwent gastric surgery and contemporaneously matched, conventionally treated obese control subjects, which reported follow-up data for subjects who had been enrolled for at least 2 years or 10 years before the analysis.
Journal ArticleDOI
Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Frank M. Sacks,George A. Bray,Vincent J. Carey,Steven R. Smith,Donna H. Ryan,Stephen D. Anton,Katherine McManus,Catherine M. Champagne,Louise M. Bishop,Nancy Laranjo,Meryl S. LeBoff,Jennifer Rood,Lilian de Jonge,Frank L. Greenway,Catherine M. Loria,Eva Obarzanek,Donald A. Williamson +16 more
TL;DR: Low-calorie diets result in clinically meaningful weight loss regardless of which macronutrients they emphasize, and improved lipid-related risk factors and fasting insulin levels.
Journal ArticleDOI
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-Year Results of the Look AHEAD Trial
Mark A. Espeland,Xavier Pi-Sunyer,George L. Blackburn,Frederick L. Brancati,George A. Bray,Renee Bright,Jeanne M. Clark,Jeffrey M. Curtis,John P. Foreyt,Kathryn Graves,Steven M. Haffner,Barbara Harrison,James O. Hill,Edward S. Horton,John M. Jakicic,Robert W. Jeffery,Karen C. Johnson,Steven E. Kahn,David E. Kelley,Abbas E. Kitabchi,William C. Knowler,Cora E. Lewis,Barbara J. Maschak-Carey,Brenda Montgomery,David M. Nathan,Jennifer Patricio,Anne L. Peters,J. Bruce Redmon,Rebecca S. Reeves,Donna H. Ryan,Monika M. Safford,Brent Van Dorsten,Thomas A. Wadden,Lynne E. Wagenknecht,Jacqueline Wesche-Thobaben,Rena R. Wing,Susan Z. Yanovski +36 more
TL;DR: At 1 year, ILI resulted in clinically significant weight loss in people with type 2 diabetes and was associated with improved diabetes control and CVD risk factors and reduced medicine use in ILI versus DSE.
Related Papers (5)
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
Michael D. Jensen,Donna H. Ryan,Caroline M. Apovian,Jamy D. Ard,Anthony G. Comuzzie,Karen A. Donato,Frank B. Hu,Van S. Hubbard,John M. Jakicic,Robert F. Kushner,Catherine M. Loria,Barbara E. Millen,Cathy Nonas,F. Xavier Pi-Sunyer,June Stevens,Victor J. Stevens,Thomas A. Wadden,Bruce M. Wolfe,Susan Z. Yanovski +18 more